Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.
Ronald A. Cantrell, PhD
Advertisement
Articles by Ronald A. Cantrell, PhD
Advertisement
Latest Updated Articles
- Pragmatic Clinical Trials: US Payers' Views on Their Value
Published: May 10th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
How Medicaid Reforms Could Deepen State Coverage Gaps
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5
